7.47

5.74% -0.455

Envveno Medical Corp (NVNO)

Overview News Price History Financials Discussions Forecast Stock Split

Envveno Medical Corp stock is traded at $7.47, with a volume of 67,605. It is down -5.74% in the last 24 hours and down -17.46% over the past month. enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Previous Close:

$7.925

Open:

$8.01

24h Volume:

67,605

Relative Volume:

1.65

Market Cap:

$5.19M

Revenue:

$186.70K

Net Income/Loss:

$-18.82M

P/E Ratio:

-0.2395

EPS:

-31.1883

Net Cash Flow:

$-14.79M

1W Performance:

-14.63%

1M Performance:

-17.46%

6M Performance:

-34.82%

1Y Performance:

-72.88%

1-Day Range:

$7.30

$8.01

1-Week Range:

$7.18

$8.80

52-Week Range:

$7.01

$28.70

Envveno Medical Corp Stock (NVNO) Company Profile

Name

Envveno Medical Corp

Sector

Healthcare (1052)

Industry

Medical Devices (143)

Phone

949-261-2900

Address

70 DOPPLER, IRVINE

Employee

Twitter

Next Earnings Date

2026-10-30

Latest SEC Filings

NVNO's Discussions on Twitter

Compare NVNO vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NVNO Envveno Medical Corp	7.47	5.19M	186.70K	-18.82M	-14.79M	-31.19
ABT Abbott Laboratories	104.89	181.50B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	94.75	121.20B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	294.66	113.02B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	44.39	64.33B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.60	49.92B	6.30B	1.07B	1.09B	1.8406

Envveno Medical Corp Stock (NVNO) Latest News

Sep 16, 2026

enVVeno Medical Corp (NASDAQ: NVNO) Activist Ownership Drops to Zero Following Complete Stake Sale - kalkinemedia.com

Sep 16, 2026

Sep 15, 2026

Two major holders fully exit enVVeno Medical Corp (NVNO) - Stock Titan

Sep 15, 2026

Braeden Lichti Files Exit Filing at enVVeno - marketscreener.com

Sep 15, 2026

Sep 14, 2026

Director Francis Duhay Sells 11 Shares of enVVeno Medical Corp (NVNO) - GuruFocus

Sep 14, 2026

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - ACCESS Newswire

Sep 11, 2026

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - The Joplin Globe

Sep 11, 2026

A medical-device CEO's presentation is now online ahead of New York meetings - Stock Titan

Sep 11, 2026

Aug 27, 2026

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - ACCESS Newswire

Aug 27, 2026

EnVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - marketscreener.com

Aug 27, 2026

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - Barchart.com

Aug 27, 2026

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - The Joplin Globe

Aug 27, 2026

Aug 21, 2026

enVVeno Medical files prospectus to offer securities for up to $100 million - scanx.trade

Aug 21, 2026

enVVeno Medical (NASDAQ: NVNO) readies $100M in potential securities sales - Stock Titan

Aug 21, 2026

Aug 14, 2026

Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants - Stock Titan

Aug 14, 2026

Aug 11, 2026

NVNO Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 8.54%Estimate Uncertainty - Vinanet

Aug 11, 2026

Aug 08, 2026

NVNO Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development CostsEPS Consistency Score - vinanet.vn

Aug 08, 2026

Aug 04, 2026

enVVeno study shows $32,000 savings per patient for venous valve therapy - scanx.trade

Aug 04, 2026

enVVeno Medical (NVNO) Highlights Cost-Effectiveness of VenoValve Amid Challenging Valuation Metrics - GuruFocus

Aug 04, 2026

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - ACCESS Newswire

Aug 04, 2026

enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient - Stock Titan

Aug 04, 2026

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - Yahoo Finance

Aug 04, 2026

enVVeno cites Journal of Vascular Surgery study showing venous valve therapy saves more than $32,000 per patient over five years - Bitget

Aug 04, 2026

Jul 31, 2026

EnVVeno Moves Toward U.S. Pivotal Trial - Orange County Business Journal

Jul 31, 2026

enVVeno Medical receives FDA approval for pivotal trial By Investing.com - Investing.com Nigeria

Jul 31, 2026

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve - Weatherford Democrat

Jul 31, 2026

Jul 30, 2026

FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO) - Stock Titan

Jul 30, 2026

Jul 29, 2026

NVNO Q2'26 Earnings: EPS estimate is (4.69) USD - TradingView

Jul 29, 2026

Jul 27, 2026